S. Agelaki

发表

Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition

S. Agelaki, M. Spiliotaki, Harris Markomanolaki, 2009, Cancer biology & therapy.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2013, British Journal of Cancer.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

S. Agelaki, V. Georgoulias, K. Syrigos, 2011, Clinical lung cancer.

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2010 .

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

S. Agelaki, V. Georgoulias, M. Perraki, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive diseases.

WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive Diseases.

A Dose Escalating Study of Oxaliplatin and High Dose Weekly Leucovorin and 5-Fluorouracil in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, D. Mavroudis, 2005, Cancer investigation.

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2005, Oncology.

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

S. Agelaki, V. Georgoulias, N. Athanasiadis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin With High-Dose Leucovorin and Infusional 5-Fluorouracil in Irinotecan-Pretreated Patients With Advanced Colorectal Cancer (ACC)

S. Agelaki, D. Mavroudis, V. Georgoulias, 2002, American journal of clinical oncology.

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.

S. Agelaki, V. Georgoulias, N. Vardakis, 2001, Lung cancer.

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of paclitaxel (P) and carboplatin (C) as second-line treatment in patients (PTS) with small-cell lung cancer (SCLC)

S. Agelaki, V. Georgoulias, G. Samonis, 1999 .

A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer

S. Agelaki, V. Georgoulias, K. Kalbakis, 2013, Cancer Chemotherapy and Pharmacology.

Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.

S. Agelaki, V. Georgoulias, J. Souglakos, 2001, Lung cancer.

A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.

S. Agelaki, V. Georgoulias, P. Malliotakis, 2000, Lung cancer.

A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2010, Anticancer research.

What's new on circulating tumor cells? A meeting report

S. Agelaki, D. Mavroudis, K. Pantel, 2010, Breast Cancer Research.

A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors

S. Agelaki, D. Mavroudis, V. Georgoulias, 2007, Oncology.

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.

S. Agelaki, V. Georgoulias, G. Samonis, 2001, European journal of cancer.

Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2010 .

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes

S. Agelaki, V. Georgoulias, K. Stylianou, 2001, British Journal of Cancer.

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.

S. Agelaki, V. Georgoulias, N. Malamos, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

S. Agelaki, G. Kallergi, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2000, American journal of clinical oncology.

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Oncology.

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

S. Agelaki, M. Ignatiadis, V. Georgoulias, 2007, Oncology.

151P Personalized approach to mammography screening during the COVID pandemic: How to make up for lost time without losing effectiveness

S. Agelaki, K. Michailidou, A. Hadjisavvas, 2022, Annals of Oncology.

A dose escalation study of weekly docetaxel in patients with advanced solid tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2000, Cancer Chemotherapy and Pharmacology.

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)

S. Agelaki, V. Georgoulias, K. Kalbakis, 1999 .

Final results of weekly paclitaxel and carboplatin plus bevacizumab as first-line treatment of triple-negative breast cancer. A multicenter phase I-II trial by the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, D. Mavroudis, 2016 .

Gemcitabine plus Irinotecan in Breast Cancer Patients Pretreated with Taxanes and Anthracyclines: A Multicenter Phase II Study

S. Agelaki, V. Georgoulias, N. Malamos, 2003, Oncology.

PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.

S. Agelaki, V. Georgoulias, P. Vorkas, 2010, The Journal of molecular diagnostics : JMD.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients

S. Agelaki, G. Kallergi, D. Mavroudis, 2011, Breast Cancer Research.

The promise of immunotherapy in head and neck squamous cell carcinoma.

S. Agelaki, A. Psyrri, P. Economopoulou, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Third Harmonic Generation microscopy as a diagnostic tool for the investigation of microglia BV-2 and breast cancer cells activation

George Filippidis, Evangelia Gavgiotaki, Sotiris Psilodimitrakopoulos, 2015, European Conference on Biomedical Optics.

A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.

S. Agelaki, V. Georgoulias, G. Samonis, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study

S. Agelaki, D. Mavroudis, V. Georgoulias, 2006, Cancer Chemotherapy and Pharmacology.

Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2010, Anticancer research.

Treatment of non-small-cell lung cancer with prolonged oral etoposide.

S. Agelaki, V. Georgoulias, G. Chalkiadakis, 1998, American journal of clinical oncology.

Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials

S. Agelaki, V. Georgoulias, J. Souglakos, 2001, Oncology.

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.

S. Agelaki, V. Georgoulias, N. Ziras, 2000, European journal of cancer.

Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.

S. Agelaki, V. Georgoulias, N. Malamos, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2002, Oncology.

First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.

S. Agelaki, V. Georgoulias, G. Chalkiadakis, 1999, American journal of clinical oncology.

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, A. Kalykaki, 2007, Oncology.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2009, British Journal of Cancer.

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.

M. Dimopoulos, S. Agelaki, V. Georgoulias, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2001, Lung cancer.

Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2003, Lung cancer.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

S. Agelaki, V. Georgoulias, N. Karachaliou, 2015, Cancer Chemotherapy and Pharmacology.

Recurrent Cerebellar Desmoplastic/Nodular Medulloblastoma in Cerebrospinal Fluid (CSF) in the Elderly. A Cytologic Diagnosis

S. Agelaki, S. Papadopoulos, A. Kalogeraki, 2016, Romanian journal of internal medicine = Revue roumaine de medecine interne.

A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2003, Anticancer research.

Phase I Study of Vinorelbine and Carboplatin Combination in Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer

S. Agelaki, V. Georgoulias, N. Malamos, 2002, Oncology.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomiz

S. Agelaki, V. Georgoulias, D. Mavroudis, 2015, Lung cancer.

Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2007, Lung Cancer.

Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC)

S. Agelaki, V. Georgoulias, G. Samonis, 1998 .

Abstract P1-04-08: Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer

S. Agelaki, G. Kallergi, V. Georgoulias, 2013 .

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

S. Agelaki, G. Kallergi, D. Mavroudis, 2011, Breast Cancer Research.

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2011, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer

S. Agelaki, V. Georgoulias, I. Boukovinas, 2014, Cancer Chemotherapy and Pharmacology.

Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin

S. Agelaki, V. Georgoulias, N. Malamos, 2003, Oncology.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

S. Agelaki, V. Georgoulias, K. Syrigos, 2010, BMC Cancer.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2014, Cancer Chemotherapy and Pharmacology.

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

S. Agelaki, V. Georgoulias, N. Malamos, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

S. Agelaki, V. Georgoulias, M. Marselos, 2007, British Journal of Cancer.

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2004, Lung cancer.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, A. Soultati, 2013, Cancer Chemotherapy and Pharmacology.

Phase III trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)

S. Agelaki, V. Georgoulias, N. Ziras, 1998 .

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumor cells in patients with early breast cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2012, British Journal of Cancer.

First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.

S. Agelaki, V. Georgoulias, G. Samonis, 1999, American journal of clinical oncology.

Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.

S. Agelaki, V. Georgoulias, G. Samonis, 2000, Seminars in oncology.

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

K. Syrigos, S. Agelaki, V. Georgoulias, 2016, Cancer Chemotherapy and Pharmacology.

Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2008, Lung cancer.

Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.

S. Agelaki, V. Georgoulias, N. Malamos, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2009, Lung cancer.

Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

S. Agelaki, V. Georgoulias, I. Boukovinas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.

S. Agelaki, V. Georgoulias, Z. Giannousi, 2011, Journal of Clinical Oncology.

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

S. Agelaki, V. Georgoulias, G. Samonis, 2004, Oncology.

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study.

S. Agelaki, V. Georgoulias, J. Souglakos, 2001, Lung cancer.

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.

M. Tzardi, S. Agelaki, V. Georgoulias, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

S. Agelaki, D. Mavroudis, V. Georgoulias, 2011, Cancer Chemotherapy and Pharmacology.

1082O_PRWOMEN 4 ONCOLOGY IN GREECE: EXPLORING COMMON CHALLENGES- SURVEY OF THE HELLENIC SOCIETY OF MEDICAL ONCOLOGY AMONG WOMEN ONCOLOGY PROFESSIONALS

S. Agelaki, A. Psyrri, H. Linardou, 2014 .

Nonlinear microscopy as diagnostic tool for the discrimination of activated T cells

George Filippidis, Sophia Agelaki, Vasilios Georgoulias, 2017, European Conference on Biomedical Optics.

Abstract P2-02-03: HER2 expression on circulating tumor cells before adjuvant chemotherapy and during follow-up in patients with HER2-negative early breast cancer

S. Agelaki, Harris Markomanolaki, G. Kallergi, 2016 .

Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer

S. Agelaki, K. Syrigos, L. Helis, 2005 .